Drug
DS 5565
DS 5565: highest development phase Phase 3, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| DS-5565 NCT02607280 | Phase 3 | Diabetic Peripheral Neuropathic Pain |
Latest
No recent events.
Follow DS 5565 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.